Search Results - "Jan De Beur, Suzanne"

High-throughput Molecular Analysis of Pseudohypoparathyroidism 1b Patients Reveals Novel Genetic and Epigenetic Defects by Danzig, Jennifer, Li, Dong, Jan de Beur, Suzanne, Levine, Michael A

“…Patients with pseudohypoparathyroidism type 1b (PHP1b) show disordered imprinting of the maternal GNAS allele or paternal uniparental disomy (UPD). Genetic…”
Get full text

A clinician's guide to X‐linked hypophosphatemia by Carpenter, Thomas O, Imel, Erik A, Holm, Ingrid A, Jan de Beur, Suzanne M, Insogna, Karl L

“…X‐linked hypophosphatemia (XLH) is the prototypic disorder of renal phosphate wasting, and the most common form of heritable rickets. Physicians, patients, and…”
Get full text

Global guidance for the recognition, diagnosis, and management of tumor‐induced osteomalacia by Jan de Beur, Suzanne M., Minisola, Salvatore, Xia, Wei‐bo, Abrahamsen, Bo, Body, Jean‐Jacques, Brandi, Maria Luisa, Clifton‐Bligh, Roderick, Collins, Michael, Florenzano, Pablo, Houillier, Pascal, Imanishi, Yasuo, Imel, Erik A., Khan, Aliya A., Zillikens, M. Carola, Fukumoto, Seiji

“…Tumor‐induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by mesenchymal tumors that secrete fibroblast growth factor 23 (FGF23). Patients…”
Get full text

Burosumab Improves Patient-Reported Outcomes in Adults With Tumor-Induced Osteomalacia: Mixed-Methods Analysis by Jan de Beur, Suzanne M, Cimms, Tricia, Nixon, Annabel, Theodore-Oklota, Christina, Luca, Diana, Roberts, Mary Scott, Egan, Shayna, Graham, Christina A, Hribal, Elizabeth, Evans, Christopher J, Wood, Sue, Williams, Angela

“…Tumor-induced osteomalacia (TIO) is an ultra-rare disease caused by tumors that secrete fibroblast growth factor 23, leading to chronic hypophosphatemia, poor…”
Get full text

Fibroblast Growth Factor 23–Mediated Bone Disease by Gonciulea, Anda R., MD, Jan De Beur, Suzanne M., MD

“…Fibroblast growth factor 23 ( FGF23 ) is an important regulator of phosphate and vitamin D metabolism and its excessive or insufficient production leads to a…”
Get full text

Burosumab for the Treatment of Tumor‐Induced Osteomalacia by Jan de Beur, Suzanne M, Miller, Paul D, Weber, Thomas J, Peacock, Munro, Insogna, Karl, Kumar, Rajiv, Rauch, Frank, Luca, Diana, Cimms, Tricia, Roberts, Mary Scott, San Martin, Javier, Carpenter, Thomas O

“…ABSTRACT Tumor‐induced osteomalacia (TIO) is caused by phosphaturic mesenchymal tumors producing fibroblast growth factor 23 (FGF23) and is characterized by…”
Get full text

Diabetic serum from older women increases adipogenic differentiation in mesenchymal stem cells by Moseley, Kendall F., Doyle, Máire E., Jan De Beur, Suzanne M.

“…Background: Paradoxically, elderly persons with type 2 diabetes mellitus (T2DM) fracture despite having higher bone density than nondiabetics. Systemic factors…”
Get full text

Goal‐Directed Treatment for Osteoporosis: A Progress Report From the ASBMR‐NOF Working Group on Goal‐Directed Treatment for Osteoporosis by Cummings, Steven R, Cosman, Felicia, Lewiecki, E Michael, Schousboe, John T, Bauer, Douglas C, Black, Dennis M, Brown, Thomas D, Cheung, Angela M, Cody, Kathleen, Cooper, Cyrus, Diez‐Perez, Adolfo, Eastell, Richard, Hadji, Peyman, Hosoi, Takayuki, Jan De Beur, Suzanne, Kagan, Risa, Kiel, Douglas P, Reid, Ian R, Solomon, Daniel H, Randall, Susan

“…ABSTRACT The American Society for Bone and Mineral Research and the United States National Osteoporosis Foundation (NOF) formed a working group to develop…”
Get full text

Challenges in the management of tumor-induced osteomalacia (TIO) by Brandi, Maria Luisa, Clunie, Gavin P.R., Houillier, Pascal, Jan de Beur, Suzanne M., Minisola, Salvatore, Oheim, Ralf, Seefried, Lothar

“…Tumor-induced osteomalacia (TIO), also known as oncogenic osteomalacia, is a rare acquired paraneoplastic disease, which is challenging to diagnose and treat…”
Get full text

Working to Increase Stability through Exercise (WISE): screening, recruitment, and baseline characteristics by Sciamanna, Christopher N, Ballentine, Noel H, Bopp, Melissa, Chinchilli, Vernon M, Ciccolo, Joseph T, Delauter, Gabrielle, Fisher, Abigail, Fox, Edward J, Jan De Beur, Suzanne M, Kearcher, Kalen, Kraschnewski, Jennifer L, Lehman, Erik, McTigue, Kathleen M, McAuley, Edward, Paranjape, Anuradha, Rodriguez-Colon, Sol, Rovniak, Liza S, Rutt, Kayla, Smyth, Joshua M, Stewart, Kerry J, Stuckey, Heather L, Tsay, Annie

“…The aim of this paper is to describe the utility of various recruitment modalities utilized in the Working to Increase Stability through Exercise (WISE) study…”
Get full text

Vaccination for Coronavirus Disease 2019 (COVID‐19) and Relationship to Osteoporosis Care: Current Evidence and Suggested Approaches by Tsourdi, Elena, Yu, Elaine W., Jan de Beur, Suzanne M., Drake, Matthew T.

“…ABSTRACT The development of coronavirus disease 2019 (COVID‐19) vaccines has proceeded at an unprecedented pace, with numerous trials conducted simultaneously…”
Get full text

Model‐Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor‐Induced Osteomalacia by Hruska, Matthew W., Sid‐Otmane, Lamia, Gosselin, Nathalie H., Quattrocchi, Emilia, Lee, Sun Ku, Mascelli, Mary Ann, Mehta, Krina, Jan de Beur, Suzanne M., Marsteller, Douglas

“…Burosumab is approved for the treatment of hypophosphatemia in persistent tumor‐induced osteomalacia. This work exemplifies a model‐informed drug development…”
Get full text

Localisation of mesenchymal tumours by somatostatin receptor imaging by de Beur, Suzanne M Jan, Streeten, Elizabeth A, Civelek, A Cahid, McCarthy, Edward F, Uribe, Liliana, Marx, Stephen J, Onobrakpeya, Olufunmilayo, Raisz, Lawrence G, Watts, Nelson B, Sharon, Michael, Levine, Michael A

“…Oncogenic osteomalacia, an acquired hypophosphataemic syndrome associated with mesenchymal tumours, is characterised by hypophosphataemia secondary to…”
Get full text

Vitamin D–Binding Protein Deficiency and Homozygous Deletion of the GC Gene by Baer, Alan N, Jan De Beur, Suzanne, Brown, Matthew A, Duncan, Emma L, Evans, David M, Hollis, Bruce W, Berg, Anders H, Karumanchi, S. Ananth, Thadhani, Ravi, Bassyouni, Hanan, Lewkonia, Raymond, Marcadier, Julien L

“…To the Editor: Henderson et al. (March 21 issue) 1 provide a detailed analysis of a 58-year-old woman with severe vitamin D deficiency related to vitamin…”
Get full text

Reply to: Burosumab for Tumor‐Induced Osteomalacia: not Enough of a Good Thing by Jan de Beur, Suzanne M., Miller, Paul D., Weber, Thomas J., Peacock, Munro, Insogna, Karl, Kumar, Rajiv, Rauch, Frank, Luca, Diana, Cimms, Tricia, Roberts, Mary Scott, Martin, Javier San, Carpenter, Thomas O.

Get full text

Tumor-Induced Osteomalacia by Jan de Beur, Suzanne M

“…Tumor-induced osteomalacia (TIO) is a rare paraneoplastic form of renal phosphate wasting that results in severe hypophosphatemia, a defect in vitamin D…”
Get full text

Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension by Briot, Karine, Portale, Anthony A, Brandi, Maria Luisa, Carpenter, Thomas O, Cheong, Hae Ii, Cohen-Solal, Martine, Crowley, Rachel K, Eastell, Richard, Imanishi, Yasuo, Ing, Steven, Insogna, Karl, Ito, Nobuaki, Jan de Beur, Suzanne, Javaid, Muhammad K, Kamenicky, Peter, Keen, Richard, Kubota, Takuo, Lachmann, Robin H, Perwad, Farzana, Pitukcheewanont, Pisit, Ralston, Stuart H, Takeuchi, Yasuhiro, Tanaka, Hiroyuki, Weber, Thomas J, Yoo, Han-Wook, Nixon, Annabel, Nixon, Mark, Sun, Wei, Williams, Angela, Imel, Erik A

“…ObjectivesTo report the impact of burosumab on patient-reported outcomes (PROs) and ambulatory function in adults with X-linked hypophosphataemia (XLH) through…”
Get full text

Discordance between Genetic and Epigenetic Defects in Pseudohypoparathyroidism Type 1b Revealed by Inconsistent Loss of Maternal Imprinting at GNAS1 by Jan de Beur, Suzanne, Ding, Changlin, Germain-Lee, Emily, Cho, Justin, Maret, Alexander, Levine, Michael A.

“…Although the molecular basis of pseudohypoparathyroidism type 1b (PHP type 1b) remains unknown, a defect in imprinting at the GNAS1 locus has been suggested by…”
Get full text

Correction to: Working to increase stability through exercise (WISE): screening, recruitment, and baseline characteristics by Sciamanna, Christopher N, Ballentine, Noel H, Bopp, Melissa, Chinchilli, Vernon M, Ciccolo, Joseph T, Delauter, Gabrielle, Fisher, Abigail, Fox, Edward J, Jan De Beur, Suzanne M, Kearcher, Kalen, Kraschnewski, Jennifer L, Lehman, Erik, McTigue, Kathleen M, McAuley, Edward, Paranjape, Anuradha, Rodriguez-Colon, Sol, Rovniak, Liza S, Rutt, Kayla, Smyth, Joshua M, Stewart, Kerry J, Stuckey, Heather L, Tsay, Annie

Get full text

Working to Increase Stability through Exercise (WISE): Study protocol for a pragmatic randomized controlled trial of a coached exercise program to reduce serious fall-related injuries by Sciamanna, Christopher, Ballentine, Noel H., Bopp, Melissa, Brach, Jennifer S., Chinchilli, Vernon M., Ciccolo, Joseph T., Conroy, Molly B., Fisher, Abigail, Fox, Edward J., Greenspan, Susan L., Jan De Beur, Suzanne, M., Kearcher, Kalen, Kraschnewski, Jennifer L., McTigue, Kathleen M., McAuley, Edward, Morone, Natalia E., Paranjape, Anuradha, Rodriguez-Colon, Sol, Rosenzweig, Andrew, Smyth, Joshua M., Stewart, Kerry J., Stuckey, Heather L.

“…Approximately one-third of older adults fall each year and fall-related injuries are a leading cause of death and disability among this rapidly expanding age…”
Get full text